Case Study: Innovative Nanosuspension Approach to Maximize API Potency in Preclinical Formulation Development
T-cell-dependent Antibody Responses and Immunopathology: A Comparative Study in Juvenile Cynomolgus Monkeys
Incidence of Neutralizing Adeno-Associated Viral Antibody Subtypes in Cynomolgus Monkeys of Cambodian, Mauritius, and Philippines Origins
Germline Integration Assessment in Preclinical Gene Therapy Studies
Key Considerations for Nonclinical AAV Gene Therapy Development
Case Study: How to Evaluate Human Abuse Potential (HAP) for CNS Drugs
Case Study—Nanosuspension Formulation to Maximize Potency for Preclinical Studies
New Findings on the Sinclair Nanopig™ in Safety Studies
Recent Scientific Data Challenges the Status Quo
Our most recent white paper presents detailed genomic, proteomic, and functional data on the Sinclair Nanopig™’s metabolism and immune systems. These findings validate this animal model as a valuable tool for regulatory pharmacology and drug safety, enhancing cross-species assessments and improving understanding of drug metabolism and potential toxicities.
The groundbreaking data also supports the use of the Sinclair Nanopig™ to reduce reliance on traditional non-rodent models in drug development.
Questions? Consult with one of our experts.
You may also be interested in the following resources:
Getting to the Heart of Science With Talita Conte
The Stories That Inspire
Meet Talita Conte, one of our dedicated scientific project managers. From São Paulo to Montréal, her journey is a testament to the power of passion and innovation in science. After making a breakthrough in myotonic dystrophy type 1 published in Nature Communications, she transitioned to project management at Altasciences, where she continues to drive fast-paced, impactful clinical trials.
